Nasdaq: GTBP

Immunotherapy for the Treatment of Cancer

Using our proprietary platform technology, GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia and multiple solid tumors.

View Product Pipeline

About

GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical stage immuno-oncology company focused on developing innovative therapies based on the Company's proprietary NK cell engager (TriKE™) technology.  TriKE™ therapeutic agents are targeted immunotherapeutic agents that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells.

About

Latest News

GT Biopharma to be Added to the Russell 2000® Index
Jun 8, 2021 • 8:00 EDT | Read More

GT Biopharma to Host Interim GTB-3550 TriKE™ Data Review Call with Dr. Jeffrey S. Miller on May 19, 2021 at 4:00 PM ET
May 18, 2021 • 9:50 EDT | Read More

Investors

GT Biopharma, Inc. Nasdaq: GTBP
Loading... Change
Loading... Volume
Loading... 52 Week Range